Literature DB >> 3258213

Graves' disease: phenotypic and functional analysis at the clonal level of the T-cell repertoire in peripheral blood and in thyroid.

M Bagnasco1, D Venuti, I Prigione, G C Torre, S Ferrini, G W Canonica.   

Abstract

We have investigated at the clonal level the repertoire of intrathyroid and peripheral T lymphocytes in three patients with Graves' disease using a high efficiency cloning technique. Clonal efficiencies ranged from 10 to 31% for intrathyroid, and from 19 to 100% for peripheral T cells. In Graves' disease the phenotypic analysis showed similar percentages of CD3+ CD4+ CD8- and CD3+ CD4- CD8+ clones in thyroid infiltrates and peripheral blood. The functional evaluation showed similar or lower proportions of cytolytic clones in thyroid infiltrates with respect to peripheral blood. Furthermore, the proportions of intrathyroid and peripheral T-cell clones capable of releasing interleukin-2 and/or gamma-interferon in response to mitogen stimulation were similar. Finally, 44% of intrathyroid clones were neither cytolytic nor able to release IL-2 and gamma-interferon. These results are strikingly different from those obtained in Hashimoto's thyroiditis, where the large majority of intrathyroid T-cell clones are cytolytic and the proportions of clones able to release gamma-IFN are remarkably increased in thyroid infiltrates when compared to those obtained from peripheral blood. Taken together, these data suggest a different role for T lymphocytes in the pathogenesis of the two major human autoimmune thyroid diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258213     DOI: 10.1016/0090-1229(88)90075-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

1.  T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy.

Authors:  A Pappa; J M Lawson; V Calder; P Fells; S Lightman
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

2.  Expression of intercellular adhesion molecule-1 (ICAM-1) on thyroid epithelial cells in Hashimoto's thyroiditis but not in Graves' disease or papillary thyroid cancer.

Authors:  M Bagnasco; A Caretto; D Olive; B Pedini; G W Canonica; C Betterle
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

3.  Molecular heterogeneity of a Graves' thyroid-infiltrating T cell population rich in CD8+ and gamma delta+ T cells.

Authors:  P Santamaria; C Lewis; J J Barbosa
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

4.  The effect of methimazole on the immune system is unlikely to operate directly on T lymphocytes.

Authors:  M Bagnasco; D Venuti; G Ciprandi; G Pesce; F Paolieri; G W Canonica
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

5.  Different intrathyroid expression of intercellular adhesion molecule-1 (ICAM-1) in Hashimoto's thyroiditis and Graves' disease: analysis at mRNA level and association with B7.1 costimulatory molecule.

Authors:  G Pesce; N Fiorino; A M Riccio; P Montagna; G Torre; C Salmaso; V Altrinetti; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

6.  Modulation of the IL-2 production defect in vitro in Graves' disease.

Authors:  Z Eisenstein; E Engelsman; M Weiss; Y Kalechman; B Sredni
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

7.  Infiltrating gamma/delta T-cell receptor-positive lymphocytes in Hashimoto's thyroiditis, Graves' disease and papillary thyroid cancer.

Authors:  F Paolieri; C Pronzato; M Battifora; N Fiorino; G W Canonica; M Bagnasco
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

8.  Dual-Directional Immunomodulatory Effects of Corbrin Capsule on Autoimmune Thyroid Diseases.

Authors:  Tianyi He; Ruxing Zhao; Yiran Lu; Wenjuan Li; Xinguo Hou; Yu Sun; Ming Dong; Li Chen
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-18       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.